Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause

Insomnia Clinical Trial

Official title:

The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00366093
• Other study ID #: 190-054
• Status: Completed
• Phase: Phase 3
• First received: August 17, 2006
• Last updated: February 21, 2012
• Start date: February 2004
• Est. completion date: January 2005

Study information

• Verified date: February 2012
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To demonstrate improved subjective sleep in women with insomnia secondary to perimenopause or menopause following treatment with 3 mg of eszopiclone.

Description:

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of eszopiclone 3 mg in women with insomnia secondary to perimenopause or menopause. Eligible subjects will be randomized to either eszopiclone 3 mg or placebo nightly for four weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 410
• Est. completion date: January 2005
• Est. primary completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria

• Subject must understand the purpose of the study and be willing to adhere to the study schedule and procedures described in this protocol.

• Subject must be between the ages of 40 and 60 years, inclusive, on the day of signing consent.

• Subject must have perimenopausal or menopausal signs and symptoms.

• Subject must report SL of >45 minutes and <6 hours of TST at least three times a week over the previous month and symptoms of insomnia must post date onset of perimenopausal or menopausal symptoms.

• Subject's physical exam must show no clinically significant abnormal findings (other than insomnia and menopause symptoms) at screening.

Exclusion Criteria

• Subject has history of circadian rhythm disorder, or travels across >3 time zones on a regular basis.

• Female subject is pregnant, lactating or within 6-months post partum.

• Subject has a history of drug or alcohol abuse or dependence in the past 2 years or positive urine drug test at screening .

• Subject has unstable medical abnormality, or unstable chronic disease; or history of significant cardiac, renal, or hepatic disease, seizure disorder, or current or past acute suicidal tendencies.

• Subject has participated in any investigational drug study within 30 days prior to screening or plans to participate in another investigational drug study during participation in this study.

• Subject is taking hormone replacement therapy or an hormonal contraceptive, and has not been on a stable dose for a minimum of 60 days prior to study start.

• Subject is known to be seropositive for HIV.

• Subject has a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption distribution, metabolism, or excretion.

• Subject has a history of malignancy within 5 years, or current malignancy, except for non-melanoma skin cancer.

• Subject has a diagnosis of any psychiatric disorder as identified by a psychiatric screening questionnaire.

• Subject has any primary diagnosis (personality disorder or mental retardation) that would impact the investigator's ability to evaluate the safety or efficacy of the study medication.

• Subject has difficulties in sleep initiation or maintenance associated with other known primary sleep disorders [e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS)], or has any condition that may affect sleep (e.g., chronic pain, urinary incontinence, etc.).

• Subject has used any drugs known or suspected to affect hepatic or renal clearance capacity within a period of 30 days prior to screening.

• Subject reports consumption of more than two alcoholic beverages daily, 14 or more alcoholic beverages weekly, or five or more alcoholic beverages on any given day.

• Subject is a rotating or third/night shift worker.

• Subject is a staff member or relative of a staff member.

• Subject is experiencing symptoms of premature menopause or surgical menopause.

• Subject has discontinued hormone replacement therapy or a hormonal contraceptive, and has not been off treatment for a minimum of 60 days prior to study start.

• Subject has been on hormone replacement therapy or hormonal contraceptives for greater then one year.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Insomnia

Intervention

Drug:
• Eszopiclone
eszopiclone 3 mg
• Placebo
placebo tablet

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mean subjective SL		Week 1	No
Secondary	mean subjective WASO		Week 1	No
Secondary	Mean subjective SL		Weeks 2, 3, 4	No
Secondary	Mean subjective WASO		Weeks 2, 3, 4	No
Secondary	Mean subjective TST		Weeks 1, 2, 3, 4	No
Secondary	Mean number of awakenings		Weeks 1, 2, 3, 4	No
Secondary	Sleep quality and depth		Weeks 1, 2, 3, and 4	No
Secondary	Daytime alertness		Weeks 1, 2, 3, and 4	No
Secondary	Ability to concentrate		Weeks 1, 2, 3, and 4	No
Secondary	Physical well-being		Weeks 1, 2, 3, and 4	No
Secondary	Ability to function		Weeks 1, 2, 3, and 4	No
Secondary	Mean subjective number of nocturnal awakenings due to hot flashes		Weeks 1, 2, 3, and 4	No
Secondary	Mean number of hot flashes per day		Weeks 1, 2, 3, and 4	No
Secondary	Mean number of nocturnal hot flashes per night		Weeks 1, 2, 3, and 4	No
Secondary	Mean severity of hot flashes		Weeks 1, 2, 3, and 4	No
Secondary	ESS score		Weeks 2 and 4	No
Secondary	ISI score		Weeks 2 and 4	No
Secondary	GCS score		Weeks 2 and 4	No
Secondary	SDS score		Week 4	No
Secondary	MenQOL score		Week 4	No
Secondary	MADRS score		Week 4	No
Secondary	Physician Global Assessment		Week 4	No
Secondary	withdrawal effects will be assessed for the ISI, ESS, MADRS, MenQOL, Greene Climacteric Scale, Sheehan Disability Scale, and Physician Global Assessment.		Week 5	No